Drug Trial Radar · NCT01109030
Pioglitazone as an Adjunct for Moderate to Severe Depressive Disorder
Last checked: Nov 20, 2026Latest source record: May 9, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Apr 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Tehran University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Pioglitazone as an adjunct to Citalopram is effective in treatment of moderate to severe depression
Conditions
- Major Depressive Disorder
Interventions
Pioglitazone+Citalopram+ChlordiazepoxideDrug
Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks
Placebo+ Citalopram+ ChlordiazepoxideDrug
Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks. Chlordiazepoxide 10 mg each night for first three weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Scores of Hamilton Depression Rating Scale (17 items) at the endTime frame: week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of psychiatry, Roozbeh psychiatric hospital, Tehran University of medical sciences
Tehran, Tehran Province, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.